From: Atypical antipsychotics in bipolar disorder: systematic review of randomised trials
 |  | Events/total patients | Event rate (%) |  |  | ||
---|---|---|---|---|---|---|---|
Event | Trials | Treatment | Active control | Treatment | Active control | Relative Risk (95% CI) | NNTp or NNH (95% CI) |
Less than 6 weeks [27, 30, 37] | Â | Â | Â | Â | Â | Â | Â |
Treatment emergent tremor | 3 | 24/331 | 26/323 | 7 | 8 | 0.9 (0.5 to 1.5) | not calculated |
Treatment emergent somnolence | 3 | 69/331 | 47/323 | 21 | 15 | 1.5 (1.1 to 2.0) | 16 (8.3 to 210) |
6–12 weeks [21, 40, 41, 42, 43] |  |  |  |  |  |  |  |
Measured weight increase >7% | 3 | 152/536 | 39/515 | 31 | 13 | 3.6 (2.6 to 5.0) | 4.8 (4.0 to 6.1) |
Treatment emergent weight gain | 3 | 62/398 | 21/380 | 16 | 6 | 2.9 (1.8 to 4.6) | 10 (7.0 to 17) |
Treatment emergent akathisia | 4 | 42/618 | 110/585 | 7 | 19 | 0.4 (0.3 to 0.5) | 8.3 (6.4 to 12) |
Treatment emergent extrapyramidal disorder | 3 | 27/511 | 148/490 | 5 | 30 | 0.2 (0.1 to 0.3) | 4.0 (3.4 to 4.9) |
Treatment emergent tremor | 4 | 39/618 | 122/585 | 6 | 21 | 0.3 (0.2 to 0.4) | 6.9 (5.5 to 9.3) |
Treatment emergent somnolence | 5 | 133/705 | 72/684 | 19 | 11 | 1.8 (1.4 to 2.4) | 12 (8.3 to 22) |
More than 12 weeks [45, 47] | Â | Â | Â | Â | Â | Â | Â |
Measured weight increase >7% | 2 | 93/340 | 43/337 | 27 | 13 | 2.2 (1.6 to 3.0) | 6.9 (4.9 to 12) |
Treatment emergent weight gain | 2 | 45/342 | 25/340 | 13 | 7 | 1.8 (1.1 to 2.8) | 17 (10 to 79) |
Treatment emergent somnolence | 2 | 64/342 | 31/340 | 19 | 9 | 2.1 (1.4 to 3.0) | 10 (6.8 to 23) |
Treatment emergent depression | 2 | 88/342 | 63/340 | 26 | 19 | 1.4 (1.1 to 1.8) | 14 (7.5 to 100) |